Common Equity: The sum of all common equity items.
Enlivex Therapeutics Ltd. (ENLV) had Common Equity of $20.63M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-3.45M |
|
-- |
|
-- |
|
$3.53M |
|
$-3.53M |
|
$0.08M |
|
$-3.45M |
|
$-3.45M |
|
$-3.45M |
|
$-3.45M |
|
$-3.45M |
|
$-3.45M |
|
$-3.53M |
|
$-3.44M |
|
23.76M |
|
23.76M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$22.65M |
|
$0.57M |
|
$1.39M |
|
$24.04M |
|
$3.14M |
|
-- |
|
$0.26M |
|
$3.41M |
|
|
Common Equity |
$20.63M |
$20.63M |
|
$20.63M |
|
23.85M |
|
| Cash Flow Statement Financials | |
$-4.62M |
|
$3.17M |
|
$0.20M |
|
$3.73M |
|
$2.48M |
|
$-1.25M |
|
$0.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.66M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.74% |
|
-16.74% |
|
-14.36% |
|
-16.74% |
|
$0.86 |
|
$-0.20 |
|
$-0.19 |
|